Moderna reported $389 million in revenue in the first quarter, but research and development spending and a $900 million legal settlement drove a $1.3 billion net loss. Moderna maintained guidance for up to 10% revenue growth in 2026. Shares fell 3% intraday on May 1.
The stellar efficacy and safety profile of Moderna's covid vaccine offered rapid validation of the firm's mRNA technology.
Moderna's Alexion partnership was terminated in 2017 after failure to find a safe but effective dose for the lead program, which could foreshadow difficulty finding a therapeutic window beyond low-dose vaccine programs.
|
Metric
|
MRNA
|
JNJ
|
BNTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 21.69 | — |
Price/Book Value | 2.54 | 6.90 | 1.04 |
Price/Sales | 8.42 | 5.88 | 6.63 |
Price/Cash Flow | — | 19.02 | — |
|
Metric
|
MRNA
|
JNJ
|
BNTX
|
|---|---|---|---|
Quick Ratio | 2.25 | 0.77 | 8.64 |
Current Ratio | 2.41 | 1.03 | 8.80 |
Interest Coverage | −131.08 | 24.09 | — |
|
Metric
|
MRNA
|
JNJ
|
BNTX
|
|---|---|---|---|
Return on Assets (Normalized) | −23.25% | 13.33% | −3.94% |
Return on Equity (Normalized) | −31.46% | 32.77% | −4.50% |
Return on Invested Capital (Normalized) | −30.55% | 20.14% | −4.61% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Rfdqwpmjl | Qgmwjvd | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Spqmgprd | Hwjbbs | $67B | |||
| argenx SE ADR
ARGX
| Vjnsjmkn | Fsqr | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Djsqthr | Fmnrh | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Knnydwrsgl | Hwknm | $25B | |||
| BioNTech SE ADR
BNTX
| Cfyxyjjg | Fqfqb | $22B | |||
| Incyte Corp
INCY
| Bdxmtmrr | Yxf | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Gvswwdfl | Dqt | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Qmlxczlz | Syddn | $13B |
/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/558ccc7b-2d37-4a8c-babf-feca8e10da32.jpg)
United States